Huangpu leads in biomedical industry growth

On March 14, Huangpu district held a special press conference on the biomedical industry.

As the core area of Guangzhou's biomedical industry, the district is home to 4,800 biomedical enterprises, experiencing explosive growth in industrial scale. It showcases characteristics such as large-scale development and innovative upgrades, forming a complete industry chain layout with Guangzhou Bioland, Guangzhou Science City, and Sino-Singapore Guangzhou Knowledge City working together.

In recent years, Huangpu has been issuing nearly 100 new drug clinical trial approvals annually, ranking first in Guangdong province for four consecutive years. The district has seen the emergence of star companies like Akeso Biotech, with multiple innovative drugs filling domestic gaps. The rapid growth of the industry has driven a surge in innovation, with five consecutive years of approval for Class I innovative drug listings, totaling nine and accounting for 50 percent of the province.

To support the listing of innovative drugs and medical devices, Huangpu has established a comprehensive innovation service model, with drug registration applications growing over three times since 2018. Simultaneously, efforts are being made to accelerate collaboration between pharmaceutical innovation and clinical medical resources, reducing the time from research and development to clinical application of innovative drugs and devices.

In terms of talent, Huangpu has systematically introduced academician teams and built a "four-chain integration" talent support system, implementing various special policies to attract numerous industry talents.

Guangzhou International Bioland. [Photo/WeChat account: gzhpfb]

Share - WeChat